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Neonatal alloimmune thrombocytopaenia (NAIT) results
from a fetomaternal incompatibility with maternal
sensitisation against a fetal human platelet antigen
(HPA) and antibodies transfer to the fetal circulation,
leading to platelet destruction. The clinical presentation
is variable and isolated intraocular haemorrhage is rare.
We present the case of a male newborn, with
intrauterine growth restriction, born at 29 weeks due to
pre-eclampsia. He presented proptosis of the left eye,
hyphaema and elevated intraocular pressure, with no
other signs of haemorrhage. Severe thrombocytopaenia
was found (27×109/L). Perinatal infection and maternal
thrombocytopaenia were excluded. Positive anti-HPA-1a
and antihuman leucocyte antigen class I alloantibodies
were found in the mother. Platelet crossmatch between
the father’s platelets and mother’s plasma was positive.
Platelet transfusions and intravenous immunoglobulin
were given with favourable response. This case
highlights an unusual presentation of NAIT, which
should be suspected in the presence of severe
thrombocytopaenia in the ﬁrst 24–72 h of life.
BACKGROUND
Neonatal thrombocytopaenia (NT) is deﬁned as a
platelet count below 150×109/L. It is found in 1–5%
of newborns at birth and in 22–35% of all newborns
admitted to neonatal intensive care units.1–3 The risk
of severe thrombocytopaenia (<50×109/L) is higher
in the more premature infants.3 NT is usually present
in one of two clinical patterns which reﬂect the most
common causes: early (within 72 h after birth) and
late (after 72 h of life). Causes of early onset NT
include placental insufﬁciency, perinatal asphyxia,
infections, autoimmune and alloimmune NT. Late
onset NT is caused by late onset sepsis and necrotis-
ing enterocolitis, among others.1 2
Neonatal alloimmune thrombocytopaenia
(NAIT) is the main cause of severe early NT, occur-
ring in 1/1000–5000 births.1 2 It is the platelet
equivalent of haemolytic disease of the newborn
and results from transplacental passage of maternal
alloantibodies directed against the fetal platelet
antigens inherited from the father and absent on
maternal platelets. These alloantibodies bind to
fetal platelets and cause their destruction, resulting
in severe fetal thrombocytopaenia and NT.1 4 In
Caucasians, about 80% of cases are due to antihu-
man platelet antigen (HPA) 1a. Unlike haemolytic
disease of the newborn, NAIToften develops in the
ﬁrst pregnancy.2–5
The clinical presentation of NAIT is variable.
While signs of skin bleeding (petechiae or bruising)
are the most common symptoms, NAIT can also
lead to lung or gastrointestinal bleeding as well as
intraocular and retinal haemorrhage (7%).6 7
However, isolated intraocular haemorrhage is rare.
The most serious complication of NAIT is an intra-
cranial haemorrhage (ICH), which can be fatal or
lead to severe sequels.3 7
Diagnostic testing includes the determination of
maternal–paternal platelet antigen incompatibility,
the detection of maternal platelet alloantibodies
and the parent’s platelet HPA genotype.6
The treatment of choice for NAIT is platelet
transfusion from an HPA-compatible donor or
washed maternal platelets. However, frequently
these options are not promptly available and these
newborns are submitted to random donor platelet
transfusion.2 3 In addition, intravenous immuno-
globulin (IVIg) can also be used as an adjuvant
therapy and intravenous methylprednisolone has
also been used.3
All newborns with a suspicion of NAIT should
be submitted to a cranial ultrasound in order to
detect an eventual ICH. Additionally, adequate
platelet counts should be maintained during the
ﬁrst 72–96 h because the risk of ICH is higher
during this period.3 5
CASE PRESENTATION
We describe the case of a male newborn from the
ﬁrst pregnancy of a non-consanguineous healthy
couple, complicated by intrauterine growth restric-
tion (IUGR). Serological maternal investigation was
irrelevant. Family medical history was normal.
There was no history of maternal thrombocyto-
paenia or haemorrhage. At 29 weeks and 6 days the
pregnancy became complicated by the occurrence
of pre-eclampsia and obstetric ultrasounds revealed
anamnios and signs of acute fetal distress.
Antibiotics were administered to the mother, lung
maturation with betamethasone was carried out
and it was decided to perform a caesarean section.
The infant was born with an Apgar score of 3/9/9,
requiring intubation and mechanical ventilation.
Birth weight was 965 g. Physical examination
revealed the presence of left eye proptosis and
haemorrhage in the anterior chamber of the eye
(hyphaema; ﬁgures 1 and 2). Ophthalmic evalu-
ation conﬁrmed the presence of hyphaema of the
left eye as well as retinal haemorrhage and elevated
intraocular pressure (16 mm Hg). There were no
signs of skin bleeding, active mucosal bleeding or
hepatosplenomegaly.
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INVESTIGATIONS
Complete blood count performed after birth revealed thrombo-
cytopaenia (27×109/L) without anaemia or altered white cell
count. Peripheral blood smear excluded platelet aggregation. An
infectious cause was also excluded (negative C reactive protein
and blood culture). Since NAIT was suspected, parental blood
testing was performed. Maternal platelet HPA phenotype was
1b1b and paternal phenotype was 1a1a. Positive anti-HPA-1a
and antihuman leucocyte antigen class I alloantibodies were
found in the mother. Platelet crossmatch between the father’s
platelets and mother’s plasma was found to be strongly positive.
Cranial ultrasound performed on the 1st, 4th and 10th days of
life showed no evidence of haemorrhage. At day 18, cranial
ultrasound showed a bilateral grade II peri-intraventricular
haemorrhage (PIVH) (Papile’s classiﬁcation).
TREATMENT
The newborn was submitted to platelet transfusion from a
random donor (15 mL/kg) in his ﬁrst hours of life and presented
a favourable response (113×109/L). However, he needed
another transfusion in the 5th and 10th days of life (thrombo-
cytopaenia of 27×109/L). Owing to previous unavailability, only
the last transfusion was from a compatible donor (HPA-1a nega-
tive), where a single dose of IVIg (1 g/kg) was also administered
(ﬁgure 3).
Intraocular elevated pressure was treated with latanoprost
from the 4th to the 23 days of life.
OUTCOME AND FOLLOW-UP
After the third platelet transfusion and IVIg a gradual platelet
increase occurred, with normalisation at day 18 (223×109/L).
The newborn never had signs of skin bleeding or mucosal
haemorrhage.
There was a gradual decrease of intraocular haemorrhage and
intraocular pressure with normalisation at day 18.
He had a late onset sepsis at day 10 with a positive blood
culture to Staphylococcus epidermidis, with a good clinical
response after 8 days of antibiotic treatment (vancomycin and
cefotaxyme).
At day 51 he was discharged home with a normal physical
examination and adequate growth.
Ophthalmic reevaluation performed at 2 months old included
a cranioencephalic and orbits MRI, which excluded the presence
of lesions or haemorrhage. Retinal imaging with Retcam
showed only a small perifoveal haemorrhage and no hyphaema.
Retinopathy of prematurity was never observed.
Cranial ultrasound at 2 months old also showed PIVH
reabsorption.
Given the increased risk of NAIT recurrence, counselling was
offered to the couple in case of another pregnancy.
DISCUSSION
NAIT is a rare and severe condition which should be suspected
in case of a severe thrombocytopaenia in the ﬁrst 72 h of life.2 6
A careful clinical history including maternal and familial back-
ground as well as investigation of other causes of neonatal
thrombocytopaenia is absolutely essential,7 since although the
mother can be asymptomatic, she or a sister may have a history
of previous affected newborns.8
NAIT’s clinical presentation and severity are variable.
Presentation varies from an incidentally detected thrombocyto-
paenia in a well newborn to life threatening in utero or post-
natal ICH.6
In the case described NAIT was not the ﬁrst diagnostic
hypothesis, because the newborn had other risk factors for
thrombocytopaenia, such as IUGR and pre-eclampsia. Also,
NAIT is infrequent in premature newborns. It is usually present
in an otherwise healthy term newborn.6 7 Nevertheless, this
newborn had a very low platelet count and, despite a favourable
initial response to random donor platelet transfusion at days 5
and 10, he needed to repeat it, thus presenting a favourable and
Figure 2 Clinical presentation: left eye proptosis and haemorrhage in
the anterior chamber of the eye (hyphaema).
Figure 1 Clinical presentation: left eye proptosis and haemorrhage in
the anterior chamber of the eye (hyphaema).
Figure 3 Treatment and platelet count response. PT, random donor
platelet transfusion; TPN, platelet transfusion from a compatible donor
(HPA-1a negative); IVIg, intravenous immunoglobulin.
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lasting response only from the second week of life and after
compatible-donor platelet transfusion and IVIg. These clinical
aspects are consistent with NAIT, which is usually resolved after
1 week.1 2 5 Initial diagnosis of NAIT was also difﬁcult due to
the absence of skin haemorrhage (the most common clinical
manifestation of NAIT). To our knowledge, this is the ﬁrst
described case of NAIT with only intraocular haemorrhage as
clinical presentation and without any other sign of
haemorrhage.
Alloimmune thrombocytopaenia probably also affected the
unborn child, justifying in part the IUGR, considering that the
association between fetal alloimmune thrombocytopaenia and
reduced birth weight in boys has also been described.9
This newborn had a PIVH at day 18 when the platelet count
was already normal (223×109/L). Probably, the factors contrib-
uting to this PIVH were the prematurity (although it usually
occurs earlier) and the late onset sepsis.
In case of suspicion of NAIT, every newborn must be submit-
ted to a cranial ultrasound in order to diagnose a possible ICH
since this is the most feared and serious complication of
NAIT.3 7
NAIT’s prognosis is usually favourable when ICH is absent,
with recovery of platelet count in 8–10 days of life.5
NAIT’s treatment is platelet transfusion, ideally from an
HPA-compatible donor or washed maternal platelets. The
threshold for transfusion is still in debate; however, transfusion
is accepted when platelet’s count is less than 50×109/L in pre-
mature newborns and less than 30×109/L in term newborns
otherwise healthy and without signs of bleeding.3
IVIg is an adjunctive therapy that can be used but it takes
longer than platelet transfusions to act. Intravenous methylpred-
nisolone has also been used, though with a lack of proven efﬁ-
cacy in studies.3
NAIT tends to be more severe in subsequent pregnancies.
Platelet antigen typing (maternal and paternal) and screening
the maternal serum for platelet antibodies should be performed
if there is a personal or familial history of a newborn affected
with NAIT. Preventive antenatal strategies should be based on
the risk of NAIT’s severity, which is higher if there is a history
of a previous infant with an early onset ICH. However, ante-
natal management remains controversial. Treatment options
include maternal weekly IVIg from 20 weeks of gestation (with
or without prednisone). It can be started earlier (from
12 weeks) if there is a higher risk of severity.10 Intrauterine
platelet transfusions are another treatment option that should be
reserved to severe or refractory cases given the risk of fetal
haemorrhage and intrauterine death.5 HPA-matched donor pla-
telets or washed maternal platelets have been proven to be
equally effective.11 Optimal approach is still a matter of debate
since there is a lack of non-invasive diagnostic methods to
measure fetal platelet counts.12 13 Nevertheless counselling is
fundamental, since later pregnancies should be managed by phy-
sicians with experience in NAIT’s diagnosis and management.14
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Learning points
▸ Neonatal alloimmune thrombocytopaenia (NAIT) should be
considered in case of severe thrombocytopaenia in the ﬁrst
72 h of life (after exclusion of other possible causes of
neonatal thrombocytopaenia).
▸ Clinical presentation is variable; isolated intraocular
haemorrhage without other signs of haemorrhage is
possible.
▸ All newborns with suspicion of NAIT must be submitted to a
cranial ultrasound to diagnose a possible intracranial
haemorrhage.
▸ NAIT treatment includes a compatible donor platelet
transfusion and IVIg as soon as possible. If adequate
platelet transfusion is not available, random donor platelets
should be used.
▸ Given the high risk of recurrence, counselling should be
offered to couples with an affected newborn in case of
subsequent pregnancies.
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